25-hydroxycholesterol targeting CRYAB aggregation for senolytic therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selectively eliminating senescent cells, particularly those induced by chemotherapeutic agents like doxorubicin, are challenging due to the heterogeneity of senescent cells and their Senescence Associated Secretory Phenotype (SASP), which complicates the identification and treatment of age-related and therapy-induced senescence-related diseases.
Innovation Solution
Targeting the crystallin alpha B (CRYAB) gene using agents such as 25-hydroxycholesterol, CLR01 molecular tweezers, or CRISPR/Cas systems to inhibit CRYAB expression and aggregation, thereby selectively killing senescent cells while sparing non-senescent cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If bulk approaches are used to study cell populations, then the complexity of analysis is reduced, but novel genes induced in small populations of senescent cells are masked and cannot be identified
Solution Approach 1:
The patent applies segmentation by dividing the cell population into individual single cells for profiling, rather than analyzing bulk populations. This allows rare senescent cells to be identified and their unique gene expression patterns to be detected without being masked by the majority non-senescent cells. The single cell approach segments the heterogeneous population to reveal subtle differences in gene expression that drive senescence-mediated outcomes.
2Reliability
If senescent cells are eliminated to treat aging and age-related diseases, then beneficial effects are achieved, but non-senescent cells may also be harmed due to lack of selective targeting
Solution Approach 1:
The patent applies local quality by using small molecule compounds that specifically target and inhibit genes or pathways uniquely activated in senescent cells, such as the SASP (senescence-associated secretory phenotype) genes. This selective inhibition allows senescent cells to be eliminated while non-senescent cells expressing different gene profiles remain unaffected. The compounds act locally on the specific molecular markers that distinguish senescent from non-senescent cells.
Solution Approach 2:
The patent employs parameter changes by identifying and targeting specific gene expression parameters that are altered in senescent cells compared to non-senescent cells. By detecting these parameter changes through single cell profiling and then using small molecules to specifically inhibit the altered parameters (such as SASP gene expression), the therapy achieves selectivity for senescent cells while preserving non-senescent cell function.
3Quantity of substance
If the number of senescent cells is low as in therapy-induced senescence, then the therapeutic target is difficult to identify, but selective elimination can provide significant therapeutic benefit
Solution Approach 1:
The patent applies preliminary action by performing single cell profiling and identifying target genes in senescent cells before administering therapeutic compounds. This preliminary identification of senescent cell-specific gene expression patterns (such as SASP genes) enables the subsequent selective targeting of these cells with appropriate small molecule inhibitors, even when the number of senescent cells is low. The preliminary characterization provides the roadmap for selective elimination.
Data Source
AI summary
Methods and compositions are provided herein that pertain to the discovery that the crystallin alpha B (CRYAB) gene and gene product provides an effective target for senolytic agents. In certain embodiments, methods of selectively killing one or more senescent cells in a subject in need thereof are provided wherein the method involves administering to the subject an effective amount of an agent that inhibits expression and/or aggregation of a CRYAB protein.